Designing targeted serotonin compounds to keep antidepressant effects but limit psychedelic effects
Structure-based Design of Selective Serotonin Biased Agonists as Chemical Probes for Psychedelic Potential
['FUNDING_R01'] · MEDICAL COLLEGE OF WISCONSIN · NIH-11321151
Researchers are creating new serotonin-targeting molecules that aim to deliver antidepressant benefits without causing psychedelic experiences for people with depression.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MEDICAL COLLEGE OF WISCONSIN (nih funded) |
| Locations | 1 site (MILWAUKEE, UNITED STATES) |
| Trial ID | NIH-11321151 on ClinicalTrials.gov |
What this research studies
From a patient perspective, scientists will build and test new molecules that selectively engage the 5‑HT2A serotonin receptor in ways that might separate antidepressant activity from hallucination-like effects. They will use detailed 3D receptor structures to design and tweak chemicals, make them in the lab, and measure how they activate different signaling pathways in cells and animal models. The team will pursue three linked aims: make constrained N‑benzyl variants to improve selectivity and bias, modify a promising scaffold to favor specific 5‑HT receptor combinations, and characterize the signaling profiles of the best compounds. Successful probes will help decide which molecules could move toward safety testing and possible future human trials.
Who could benefit from this research
Good fit: Adults with major depressive disorder who want faster-acting treatments but prefer to avoid psychedelic experiences would be the likely candidates for future trials based on this work.
Not a fit: People whose depression is driven by non‑serotonergic causes or those seeking psychedelic-assisted psychotherapy may not benefit from non‑psychedelic 5‑HT2A agonists.
Why it matters
Potential benefit: Could lead to new antidepressant drugs that act quickly and last long without producing psychedelic side effects.
How similar studies have performed: Classic psychedelics have shown rapid, durable antidepressant effects in clinical studies, but designing selective non‑psychedelic 5‑HT2A agonists is a novel and largely untested strategy.
Where this research is happening
MILWAUKEE, UNITED STATES
- MEDICAL COLLEGE OF WISCONSIN — MILWAUKEE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MCCORVY, JOHN D — MEDICAL COLLEGE OF WISCONSIN
- Study coordinator: MCCORVY, JOHN D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.